Zacks Investment Ideas feature highlights: Intuitive Surgical's
For Immediate Release
Chicago, IL – October 24, 2025– Today, Zacks Investment Ideas feature highlights Intuitive Surgical's ISRG.
Buy the Post-Earnings Surge in Intuitive Surgical Stock?
Intuitive Surgical's stock has been on a tear since the medical pioneer exceeded Q3 expectations on Tuesday and provided positive guidance that left investors hyped about rising demand for robotic-assisted surgical systems.
Surging more than +15% since its Q3 report, Intuitive Surgical stock has moved into positive territory for the year and has started to rebound closer to its 52-week and all-time high of $616 a share.
Intuitive Surgical's Strong Q3 Results
Posting Q3 sales of $2.5 billion, Intuitive Surgical's top line increased from $2.03 billion in the comparative quarter and topped estimates of $2.41 billion. Most intriguing is that Intuitive Surgical's revenue from instruments and accessories used in each procedure grew 22%, reflecting both higher procedure volume and increased utilization per system.
Thanks to its operational efficiency and strategic execution, Intuitive Surgical's earnings soared 30% to $2.40 per share compared to EPS of $1.84 in Q3 2024. Furthermore, this crushed Q3 EPS expectations of $1.99 by 20%.
Rising Demand for Robotic-Assisted Procedures
Aiding Intuitive Surgical's strong results and positive outlook was that the company saw a 20% increase in global surgeries using its da Vinci robotic systems. Notably, da Vinci is a cutting-edge robotic platform designed to enhance precision and control in minimally invasive surgeries, including for urology, gynecology, cardiothoracic procedures, and general surgery.
Similarly, Intuitive Surgical's Ion endoluminal system has also increased in popularity, particularly in lung biopsy procedures. Regarding its strategic execution, Intuitive Surgical's product adoption was also driven by higher system placements, placing 427 da Vinci systems in hospitals and surgical centers during Q3 2025, compared to 379 in the prior year quarter.
Innovation and regulatory wins have further propelled Intuitive Surgical's operations. To that point, FDA-cleared software upgrades are boosting its upgraded product line, especially as it relates to improvements in diagnostic capabilities.
Intuitive Surgical's Raised Guidance
Citing strong hospital spending and international expansion, Intuitive Surgical raised its full-year da Vinci procedure growth expectations to 17%-17.5%, up from previous forecasts of 15.5%-17%. Additionally, Intuitive Surgical raised projections for its full-year pro forma gross margin range to 67%-67.5% from 66%-67%.
Based on Zacks' estimates, Intuitive Surgical's total sales are expected to spike 18% this year and are projected to expand another 12% in fiscal 2026 to $11.12 billion. Intuitive Surgical's annual earnings are currently slated to rise 11% in FY25 and are projected to increase another 12% in FY26 to $9.16 per share.
Conclusion & Final Thoughts
Following the sharp post-earnings rally, Intuitive Surgical stock lands a Zacks Rank #3 (Hold). Trading at a noticeable but not overly stretched premium of 64X forward earnings, a buy rating could be on the way for ISRG if the rally doesn't get overdone from here.
Like AI, the adaptation and growth prospects for robotics are very luring to investors, and EPS revisions are likely to trend higher for Intuitive Surgical following its favorable Q3 report. This could help in normalizing a somewhat lofty valuation, with it very enticing that Intuitive Surgical has expanded its installed base to over 10,000 systems, boosting recurring revenue from instruments and accessories.
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.
Today you can access their live picks without cost or obligation.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performancefor information about the performance numbers displayed in this press release.
Zacks Names #1 Semiconductor Stock
This under-the-radar company specializes in semiconductor products that titans like NVIDIA don't build. It's uniquely positioned to take advantage of the next growth stage of this market. And it's just beginning to enter the spotlight, which is exactly where you want to be.
With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $971 billion by 2028.
See This Stock Now for Free >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Source Zacks-com
